Skip to main content
AB Science logo

AB Science — Investor Relations & Filings

Ticker · AB ISIN · FR0010557264 LEI · 969500U43TVR8CCVBJ97 PA Manufacturing
Open in API
Filings indexed 742 across all filing types
Latest filing 2019-08-05 Regulatory Filings
Country FR France
Listing PA AB

About AB Science

https://www.ab-science.com

AB Science is a clinical-stage pharmaceutical company that researches, develops, and markets protein kinase inhibitors for human and veterinary medicine. The company focuses on developing innovative drugs for diseases with high unmet medical needs. Its pipeline is centered on two main compounds: masitinib and AB8939. Masitinib, a highly selective tyrosine kinase inhibitor, is under investigation for treating neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS) and Alzheimer's disease, as well as inflammatory diseases like mastocytosis. AB8939 is a microtubule destabilizer being developed for oncology, specifically for Acute Myeloid Leukemia (AML). The company also commercializes masitinib in veterinary medicine under the brand name Masivet®.

Recent filings

Filing Released Lang Actions
AB Science fait le point sur le programme clinique du masitinib
Regulatory Filings Classification · 1% confidence The document is a press release dated August 5, 2019, titled "Point sur le programme clinique du masitinib" (Update on the masitinib clinical program). It details the company's strategy to rationalize its clinical portfolio, lists seven target indications, and provides timelines for Phase 3 results (e.g., Q3 2019, Q4 2019, 2020). It also includes a detailed table comparing market size and competitors for these indications. This content is characteristic of an update on ongoing research and development activities, often released to investors to provide operational and strategic progress reports outside of mandatory periodic financial filings. Since it is a detailed update on clinical progress and strategy, it aligns best with an Investor Presentation (IP) or a detailed Management Report (MDA). Given the focus on clinical pipeline milestones and strategic prioritization, it functions as an Investor Presentation providing forward-looking operational details. It is not a formal financial report (10-K, IR), an earnings release (ER), or a transcript (CT). It is a strategic update aimed at investors.
2019-08-05 French
AB Science provides an update on its masitinib clinical program
Management Reports Classification · 1% confidence The document is dated August 5, 2019, and is titled "Update on masitinib clinical program." It details strategic decisions regarding clinical trials, expected results timelines (Q3 2019, Q4 2019, 2020, 2021), and provides extensive tables comparing market sizes and competitors for various indications. This content strongly suggests an update on ongoing business operations and pipeline progress, which is typical of an Earnings Release (ER) or a detailed Management Discussion & Analysis (MDA). Since it focuses heavily on the clinical pipeline status, expected results, and strategic focus rather than just summarizing the period's financial performance (which would be ER), it aligns best with a Management Report/Discussion (MDA) providing operational and strategic context, often released concurrently with earnings or as a significant operational update. Given the focus on clinical program rationalization and future milestones, MDA is the most appropriate fit over a general ER.
2019-08-05 English
AB Science today reports the analysis for its phase 3 trial evaluating masitinib in patients with non-resectable or metastatic stage 3 or stage 4 melanoma
Earnings Release Classification · 1% confidence The document is a press release dated August 2, 2019, announcing new clinical results for the drug Masitinib in oncology, specifically detailing Phase 3 trial data (primary endpoint, ORR, p-values) and the company's decision regarding future development in that indication. This content is characteristic of an Earnings Release (ER) or a general press announcement regarding operational/clinical progress, which often precedes or accompanies formal financial filings. Since it focuses on clinical trial outcomes and strategic updates rather than comprehensive financial statements (like 10-K or IR) or a formal transcript (CT), the most appropriate classification is Earnings Release (ER), as these announcements typically contain the key operational highlights that drive investor interest, even if the primary focus here is clinical data rather than quarterly revenue figures. It is not a formal regulatory report, a presentation, or a management discussion, but a direct announcement of significant operational news. FY 2019
2019-08-02 English
AB Science annonce aujourd’hui les résultats de son étude de phase 3 évaluant le masitinib chez des patients atteints de mélanome non opérable ou métastatique de stade 3 ou stade 4
Earnings Release Classification · 1% confidence The document is a press release dated August 2, 2019, from AB Science announcing new clinical results for its drug masitinib in metastatic melanoma. It details study design (Phase 3, AB08026), efficacy endpoints (objective response rate), and specific numerical outcomes (39.1% response rate in first-line treatment). This content structure—announcing key financial/clinical results for a specific period or trial update—aligns perfectly with an Earnings Release (ER), which covers periodical financial results and key highlights, or potentially an Investor Presentation (IP) if it were structured as slides, but the format here is a formal announcement of results. Since it is a structured announcement of clinical trial outcomes, which often accompany or precede formal earnings reports, it fits best under the 'Earnings Release' category (ER) as it communicates the 'results' of a key business activity (drug development). It is not a full Annual Report (10-K), a transcript (CT), or a general regulatory filing (RNS). Given the focus on announcing specific, quantified results, ER is the most appropriate classification. FY 2019
2019-08-02 French
AB Science annonce la publication de l’étude positive de phase 2/3 du masitinib dans la SLA dans la revue Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
Investor Presentation Classification · 1% confidence The document is a press release dated July 8, 2019, announcing the publication of positive Phase 2/3 study results for the drug masitinib in ALS in the peer-reviewed journal 'Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration'. It details the study outcomes (efficacy, safety, statistical significance) and includes quotes from principal investigators and medical experts. It also provides background on ALS and the drug itself, concluding with standard corporate boilerplate and forward-looking statements. This content strongly aligns with an Earnings Release (ER) or a detailed announcement of clinical/research progress, which often accompanies or precedes a formal financial filing. Since it focuses heavily on clinical trial results and publication, it is best classified as an Earnings Release (ER) as it communicates key performance/development milestones, or potentially an Investor Presentation (IP) if it were structured as slides, but given the press release format detailing results, ER is the closest fit among the options for communicating significant operational/research achievements that impact valuation. However, looking closely at the definitions, this is primarily an announcement about a scientific publication and clinical trial results, not a standard quarterly financial summary (ER) or a formal presentation deck (IP). It is a specific announcement of a major scientific milestone. Since there is no specific category for 'Clinical Trial Result Announcement' or 'Scientific Publication Announcement', we must choose the best fit. It is not a formal financial report (10-K, IR), nor a management discussion (MDA). It is a detailed update on R&D progress. Given the options, 'ER' (Earnings Release) is often used broadly for major positive news releases, but 'IP' (Investor Presentation) sometimes covers detailed scientific updates presented to investors. Since this is a press release announcing the *publication* of results, and it is not a short notice about a report being available (which would be RPA/RNS), it functions as a detailed communication of value-driving information. In many databases, detailed clinical updates are grouped with ERs or IPs. Given the depth of scientific detail, 'IP' (Investor Presentation) is a strong candidate, but 'ER' is often the default for major positive news releases. Let's re-evaluate based on the content: it's a detailed scientific update, not a financial summary. If we consider 'IP' as a general investor communication piece detailing strategy/progress, it fits well. If we must choose between ER and IP, ER usually implies financial figures (which are present here only in terms of clinical endpoints, not revenue/profit). Given the focus on the study publication and expert commentary, it functions as a high-level investor update. I will classify it as an Investor Presentation (IP) as it is a detailed communication of R&D progress intended for investors, even though it's formatted as a press release. If IP is too broad, ER is the next best fit for a major positive announcement. Given the context of a pharmaceutical company, clinical trial results are paramount news. I will lean towards ER as the primary vehicle for communicating major operational/development news that impacts valuation, even if financial statements aren't the focus. However, the document is purely about a scientific publication. Let's check if it fits 'RPA' (Report Publication Announcement). It announces the publication of the study in a journal, which is a type of report publication. But it contains extensive analysis and commentary, making it more than just a simple announcement of availability. Therefore, it is a substantive communication. I will select 'IP' as it is a detailed presentation of key progress to the investment community, which is the function of an Investor Presentation. Revisiting the definitions: ER is 'Initial announcement of quarterly/periodical financial results (key highlights only)'. This is not financial results. IP is 'Detailed presentation for investors focusing on financials, strategy, and market position'. This document focuses heavily on strategy/pipeline progress. This is the best fit for a detailed, non-financial regulatory/research update aimed at investors.
2019-07-08 French
AB Science announces the publication of the positive phase 2/3 clinical trial with masitinib in ALS in the journal Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
Regulatory Filings Classification · 1% confidence The document is a press release dated July 8th, 2019, announcing that the full, peer-reviewed results of a clinical trial (masitinib in ALS) have been published in a scientific journal ('Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration'). It details the positive outcomes, quotes key researchers, and provides references to the published article. This is not a comprehensive annual report (10-K), an interim report (IR), or a standalone audit report (AR). It is an announcement about the publication of scientific data, which is a form of regulatory or corporate communication. Since it is an announcement detailing the release of specific scientific/clinical findings, and it is not a general earnings release (ER) or a general regulatory filing (RNS), the most fitting category is one that covers specific corporate updates. Given the content focuses heavily on clinical trial results and their publication, it is a specific corporate update. However, looking at the definitions, it is not a standard financial report. It is an announcement of scientific progress. If it were an Investor Presentation (IP), it would likely contain slides or a more structured presentation format. Since it is a formal announcement of a major corporate/scientific milestone (publication of key trial data), and it is not explicitly covered by other categories like ER, DIV, or CAP, it falls best under the general 'Regulatory Filings' (RNS) as a significant, non-standard announcement, or potentially an Investor Presentation (IP) if the intent is to inform investors about scientific progress. Given the structure is a press release announcing a publication, RNS is the safest fallback for significant, non-standard announcements. However, the content is highly specific to clinical trial results, which often accompany Investor Presentations (IP) or are detailed in specific scientific updates. Since the document is a detailed press release about the publication of clinical data, and not just a brief notice of publication, it leans away from RPA/RNS. It functions as a detailed update for investors on R&D progress. I will classify it as an Investor Presentation (IP) because it provides detailed scientific and clinical data intended for investor consumption regarding the company's pipeline progress, even though it's formatted as a press release announcing the journal publication.
2019-07-08 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.